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Background: Extrahepatic portal-vein obstruction (EHPVO) is a common cause of portal hypertension in
developing countries. The main risk in pregnant women with this condition is variceal bleeding, which
may be life-threatening. The objective of our study was to assess the outcome of pregnancy in women
with EHPVO.
Materials and Methods: A retrospective analysis of 21 pregnancies in 12 women with EHPVO was carried
out at a tertiary hospital in India.
Results: The mean age of pregnant womenwith EHPVO was 25.3 years, and the mean duration of disease
since diagnosis was 6.1 ± 1.2 years. All the patients had chronic EHPVO, and two patients were diagnosed
in the index pregnancy. The incidence of abortion, preterm deliveries, and small for gestational age fetus
was 23.8%, 18.7%, and 12.5%, respectively. Thrombocytopenia was found to complicate 61.9% of the
pregnancies, while anemia was detected in 40% of the pregnancies. Variceal bleeding occurred in one
woman, who was diagnosed during pregnancy and was managed successfully with endoscopic sclero-
therapy. None of the patients who were diagnosed prenatally had variceal bleeding during pregnancy.
The outcome in nine pregnancies, in which prenatal endoscopic variceal ligation was done, was
compared with eight pregnancies, in which endoscopic sclerotherapy was done. No signiﬁcant difference
between the two groups in terms of pregnancy outcome and complications was found. There were no
stillbirths or maternal mortality.
Conclusion: Women with EHPVO who have been diagnosed and treated prenatally have a good preg-
nancy outcome. They should be managed in a tertiary care center with a multidisciplinary approach.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Extrahepatic portal-vein obstruction (EHPVO) is deﬁned as
obstruction of the extrahepatic portal vein with or without the
involvement of the intrahepatic portal veins or splenic or superior
mesenteric veins [1]. In developing countries, it is a common cause
of portal hypertension, accounting for up to 30% of all variceal
bleeders [2]. In Western countries, only 5e10% of variceal bleeders
are due to this condition [3]. Adult-onset EHPVO is a heterogeneous
entity with regard to etiology, but is frequently associated with one
or several risk factors for thrombosis, like myeloproliferative dis-
orders, or deﬁciencies of protein C and protein S [4]. However, these
risk factors have not been adequately studied in Asian patients.
In pregnancy, the increased blood volume and cardiac output
increase portal ﬂow and aggravate portal hypertension in theseand Gynecology, Room Num-
avi, Bangalore 560072, India.
baiah).
bstetrics & Gynecology. Publishedpatients. This increases the risk of variceal bleeding in pregnant
EHPVO patients, which can compromise the perinatal outcome [5].
Prenatal obliteration of high-risk varices by endoscopic sclero-
therapy (EST) or endoscopic variceal ligation (EVL) reduces the risk
of variceal bleeding, and can improve the pregnancy outcome in
these women [6].
We report our experience with 21 pregnancies in 12 women
with EHPVO. We assessed the clinical proﬁle, risk factors, and
fetomaternal outcome in pregnant women with EHPVO.
Materials and methods
In a retrospective study, we observed thematernal and perinatal
outcome of 21 pregnancies in 12 women with EHPVO who were
managed at a tertiary care hospital in India during the years
2006e2012. The diagnosis of EHPVO was made on the basis of
Doppler ultrasonographic ﬁndings (replacement of portal vein by
venous collateralsdportal cavernoma) and by the presence of other
features of portal hypertension, like splenomegaly and endoscopicby Elsevier Taiwan LLC. All rights reserved.
Table 2
Details of the therapeutic interventions performed.
Therapy (n ¼ 12) No. (%)
Therapy prior to pregnancy 10 (83.3%)
EVL 5
EST 3
Shunt surgery with splenectomy 2
Therapy during pregnancy 2 (16.7%)
EST 1
EVL 1
EST ¼ endoscopic sclerotherapy; EVL ¼ endoscopic variceal ligation.
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cirrhosis and noncirrhotic portal ﬁbrosis, and those positive for
hepatitis B and C were excluded from the study.
Details regarding clinical presentation, duration of the disease,
treatment received, and obstetric history were noted. Laboratory
investigations, including complete blood count, liver function test,
and coagulation proﬁle of the patients, were recorded in detail.
These women were managed under the joint supervision of ob-
stetricians and gastroenterologists.
They were regularly seen in antenatal clinic every 2 weeks, until
28 weeks, and thereafter, weekly until delivery. Patients with
thrombocytopenia were admitted at term. An upper gastrointes-
tinal endoscopy (UGIE) was performed at the ﬁrst visit, if indicated.
High-grade varices, with or without bleeding, were managed by
endoscopic interventions (EST or EVL). In the presence of upper
gastrointestinal bleeding, EST using absolute alcohol or EVL using a
multiple band applicator was done. Cesarean sections and induc-
tion of labor were done only for obstetric indications.
The incidence of antenatal complications, medical complica-
tions (anemia, thrombocytopenia, variceal bleeding, and jaundice),
and perinatal outcome (Apgar score, birth weight, preterm delivery,
and stillbirth) was noted. The women were divided into two
groups: patients with EHPVO who had undergone EST in the past
and patients with EHPVO who had undergone EVL. The afore-
mentioned determinants were compared between these two
groups. The categorical variables between the two groups were
compared using Fisher's exact test with p < 0.05 being considered
statistically signiﬁcant.
Results
A total of 21 pregnancies in 12 women with EHPVO were
analyzed. The mean age of the womenwas 25.3 ± 2.1 years, and the
mean duration of disease since diagnosis was 6.1 ± 1.2 years
(Table 1). Two patients were diagnosed during pregnancy: pre-
sentingwith abdominal lump in one and variceal bleed in the other.
Both presented at 4 months of pregnancy with Grade 3 varices, and
underwent EVL and EST, respectively. All the patients had chronic
EHPVO. Two patients were previously operated (splenorenal shunt
and splenectomy); ﬁve patients had undergone EVL and three pa-
tients had undergone EST in the past (Table 2). None of the patients
were found to have underlying prothrombotic state.
Thrombocytopenia was the most common disease-associated
complication, being seen in 61.9% of the pregnancies (Table 3).
Severe thrombocytopenia (<50,000/mm3) was present in 28.6% of
the pregnancies, while anemia (hemoglobin <11 g/dL) complicated
40% of the pregnancies. There was no variceal bleed in any of theTable 1
Baseline characteristics of patients with extrahepatic portal-vein
obstruction (n ¼ 12).
Maternal characteristics Number (%)
Age of the patients (y)a
Mean ± SD 25.3 ± 2.1
Obstetric history
Primigravida 6 (50%)
Time since diagnosis (y)
Mean 6.1 ± 1.2
During pregnancy 2 (16.7%)
Presenting complaint
Variceal bleeding 8 (66.6%)
Abdominal lump 2 (16.7%)
Epistaxisb 2 (16.7%)
SD ¼ standard deviation.
a At the time of last pregnancy.
b Due to thrombocytopenia.pregnancies, in which the diagnosis was made prenatally (n ¼ 19).
UGIE was done in eight of these pregnancies, and residual varices
were found to complicate two of them. These Grade 1 residual
varices were not treated further. High-grade varices were not found
in any of these patients. In the rest of the pregnancies, UGIE was not
done, as they had undergone the procedure shortly before
conceiving. Among the two patients who were diagnosed during
pregnancy, one presented with variceal bleed and underwent EST.
The other patient presented with splenomegaly, and on UGIE was
found to have Grade 3 varices and underwent prophylactic EVL.
Both of these patients tolerated the procedure well, and had no
further variceal bleed and went on to deliver at term. None of the
pregnancies were complicated by jaundice, ascites, and pancyto-
penia, and there was no maternal mortality.
The incidence of abortion was 23.8%, and the majority of these
(four out of ﬁve) were ﬁrst-trimester abortions. One patient had
preeclampsia and another had gestational diabetes mellitus.
Abruptio placentae did not complicate any pregnancy. The gesta-
tional age at delivery was 37.4 ± 1.4 weeks. Out of a total of 16 live
births, 12 were vaginal deliveries and four were delivered by
caesarean section. All the cesareans were done for obstetric in-
dications. One patient had postpartum hemorrhage (atonic), which
was controlled with an oxytocin drip.
The mean birth weight was 2.6 ± 0.4 kg, and the incidence of
preterm delivery and small for gestational age fetus was 18.7% and
12.5%, respectively (Table 4). There were no stillbirths, neonatal
deaths, or any congenital anomaly. For two babies, the Apgar scores
at 5 minutes was less than 8. Both required admission to the
neonatal intensive care unit and were eventually discharged.
We compared the outcome in nine pregnancies, in which pre-
natal EVL was done with eight pregnancies, in which prenatal EST
was done. Thrombocytopenia complicated 75% of pregnancies with
prenatal ESTcomparedwith 66.7% in pregnancies with prenatal EVL
(p > 0.05). The incidence of residual varices, preterm delivery, and
lowbirthweightwas found to be similar in both groups. None of the
patients in either grouphad variceal bleed in any of the pregnancies.Table 3
Maternal complications in 21 pregnancies in women with EHPVO.
Maternal complicationsa No. (%)
Disease-associated complications
Variceal bleeding 1 (4.7%)
Thrombocytopenia (<1.5  105/mm3) 13 (61.9%)
Ascites 0
Jaundice 0
Residual varices 2 (9.5%)
Mortality 0
Obstetric complications
Abortion 5 (23.8%)
Gestational diabetes 1 (4.7%)
Preeclampsia 1 (4.7%)
Abruption 0
Postpartum hemorrhage 1 (4.7%)
EHPVO ¼ extrahepatic portal-vein obstruction.
a In 21 pregnancies.
Table 4
Perinatal outcome in pregnant women with EHPVO.
Perinatal outcomea No. (%)
Total newborns 16
Live born 16
Stillbirth 0
Preterm births 3 (18.7%)
Mean age of gestation (wk) 37.4 ± 1.4
Mean birth weight (kg) 2.6 ± 0.4
Birth weight <2.5 kg 5 (31.2%)
Intrauterine fetal complications
Intrauterine growth restriction 2 (12.5%)
Oligohydramnios 0
Newborn with Apgar < 8 2 (12.5%)
EHPVO ¼ extrahepatic portal-vein obstruction.
a In 16 pregnancies, which continued beyond 20 weeks of gestation.
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In developing countries, like India, EHPVO is the most common
cause of portal hypertension, unlike Western countries, where
portal hypertension is usually due to cirrhosis [7]. Also, these
women with EHPVO have normal fertility, unlike women with
cirrhosis who have reduced fertility and up to 40% fetal-loss rate [8].
However, data regarding the pregnancy outcome and complica-
tions in patients with EHPVO are sparse, and there is a lack of large
case studies.
Pregnancy aggravates portal hypertension in these patients. This
is because of the increased blood volume, increased cardiac output,
and mesenteric vasodilatation [9]. Increasing intra-abdominal
pressure in the second and third trimesters also contributes to
portal hypertension by increasing the inferior vena cava pressure
[10]. This results in rerouting of blood via gastroesophageal col-
laterals, and increases the risk of variceal bleeding.
The presentation could be either acute (recent) or chronic
EHPVO. Patients with acute EHPVO usually present with abdominal
pain, ascites, jaundice, or fever [2]. In these patients, there is no
evidence of portosystemic collaterals and portal cavernoma. The
majority of patients with chronic EHPVO present with repeated
bleeding episodes from esophageal varices. In our study, all the
patients had chronic EHPVO, and eight of the 12 patients presented
with variceal bleeding. Two patients presented with epistaxis, and
on workup, were found to have thrombocytopenia due to spleno-
megaly and EHPVO.
The underlying hypercoagulable and prothrombotic state is
thought to be an important risk factor for the development of
EHPVO [4,11]. Investigations to detect an underlying myeloprolif-
erative disorder; factor V Leiden mutation; G20210 A prothrombin
gene mutation; and levels of protein C, S, and antithrombin III need
to be conducted in all patients with EHPVO. However, these in-
vestigations are more likely to be rewarding in Western patients
than in Asian patients [2]. Aggarwal et al [12] retrospectively
analyzed 26 pregnancies in 14 women with EHPVO, and found an
underlying hypercoagulable state in 21% of the women. However,
Mandal et al [6], who studied 41 pregnancies in 24 women with
EHPVO, did not ﬁnd any underlying hypercoagulable state in any of
their patients. In our study, we also did not ﬁnd any prothrombotic
state in any of our patients.
The incidence of variceal bleeding in pregnancy in patients with
EHPVO has been reported to range from20% to 34% [5,13]. However,
it is generally agreed that patients with a prenatal diagnosis of
EHPVO have amuch lower incidence of variceal bleeding compared
to those who are diagnosed during pregnancy [6]. Aggarwal et al
[12] reported that none of their 14 patients had new onset variceal
bleeding during the course of index pregnancy. In our study, noneof the patients who were diagnosed prenatally had variceal
bleeding during pregnancy. This was probably because all these
patients had undergone prenatal endoscopic obliteration of varices,
or had undergone prior splenectomy with shunt surgery. However,
two of these patients were found to have residual varices during
pregnancy. Both of these residual varices were Grade 1, and these
varices were not treated. Although it is generally recommended
that all varices detected during pregnancy should be treated [2], the
efﬁcacy of this treatment in low-grade varices is not known. More
studies are needed to address this issue. Only one patient in our
study had variceal bleeding. In this patient, the diagnosis of EHPVO
was made at 4 months of pregnancy when the patient presented
with variceal bleed and splenomegaly. She underwent UGIE, which
detected Grade 3 varices, and EST was done.
For the control of acute variceal bleeding and for secondary
prophylaxis of variceal bleeding, endoscopic therapy is effective
and EVL is preferred [1,2]. Primary prophylaxis by EVL is recom-
mended for high-risk varices before pregnancy. Either beta-
blockers or endoscopic therapy can be used for primary prophy-
laxis of variceal bleeding in patients not planning pregnancy [2,14].
Beta-blockers reduce the portal pressure by reducing the cardiac
output and by causing splanchnic vasoconstriction [9]. However, if
used during pregnancy, they can cause fetal bradycardia and
growth retardation [15]. Further, there are no studies, which have
evaluated the safety and efﬁcacy of beta-blockers in pregnant pa-
tients with EHPVO. Patients not responding to EST or EVL require
deﬁnitive surgery.
According to the report of the Baveno V consensus workshop,
EVL is the recommended form of therapy for acute variceal
bleeding, although the safety of EST in pregnancy has also been
established [1]. However, there are no studies that have compared
pregnancy complications in patients who underwent either of the
two techniques prenatally. In our study, we compared the outcome
in nine pregnancies, in which prenatal EVL was done with eight
pregnancies, inwhich EST was done.We did not ﬁnd any signiﬁcant
difference between the two groups in terms of pregnancy outcome
and complications. As this ﬁnding was limited by the small sample
size, a larger study is needed to conﬁrm this.
Thrombocytopenia due to splenomegaly is one of the major
complications in these patients and has to be corrected before
delivery. Aggarwal et al [12] reported that 50% of their 14 patients
received platelet transfusion intrapartum. In our study, platelet
transfusion was given in 30% of the patients during delivery.
However, 61.9% of the pregnancies were complicated by throm-
bocytopenia, making it the most common complication in
pregnancy.
The obstetric outcome of our patients with EHPVO was almost
similar as that in general population, except for increased incidence
of abortion (23.8%). Prenatal detection and treatment of these pa-
tients were probably responsible for this good outcome. In a
retrospective study, Sumana et al [13], who studied 12 pregnancies
in ﬁve women with noncirrhotic portal hypertension, reported no
preterm delivery or stillbirth. However, four babies (44%) were
small for gestational age. Mandal et al [6] found a higher incidence
of preterm delivery, low birth weight, and stillbirth among preg-
nant women who were diagnosed for the ﬁrst time in pregnancy
and presented with variceal bleed.
Prenatal evaluation and optimization of women with EHPVO is
the key to improve pregnancy outcome in them. Investigations to
ﬁnd out any underlying prothrombotic condition and other base-
line investigations, like complete blood count, liver function test,
and UGIE, should be done in all these patients. Endoscopic therapy
of the varices in the form of either ESTor EVL should be done before
conception, and patients not responding to them should undergo
decompression surgery. Splenectomy without shunt surgery
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chronic EHPVO is not clear. However, in patients with documented
prothrombotic disorders, lifelong thromboprophylaxis is recom-
mended [1]. Repeat endoscopic evaluation is usually done during
pregnancy, and either EST or EVL may be used to obliterate the
residual varices.
Cesarean delivery is reserved only for obstetric indications. The
delivery should be monitored closely, and second stage of labor
may be cut short by operative vaginal delivery in patients who are
at risk [2]. Intravenous ﬂuids should not be administered over-
zealously because of the risk of volume overload and variceal
bleeding. Platelet transfusion is required intrapartum if the count is
less than 50,000/mm3.
In conclusion, women with EHPVO would have a good preg-
nancy outcome if they were managed in a tertiary care center with
a multidisciplinary approach.
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